DENVER—Higher parathyroid hormone (PTH) levels are associated with an increased prevalence of metabolic syndrome in non-diabetic patients with CKD, data show.
Georges Saab, MD, of Washington University in St. Louis, and collaborators reported that higher PTH may be a predictive marker of disease. The researchers conducted a cross-sectional analysis of 3,215 non-diabetic patients in the National Kidney Foundation’s Kidney Early Evaluation Program. In unadjusted analysis, the researchers found that the prevalence of metabolic syndrome increased along with increasing PTH quartiles (31.7%, 33.8%, 37.3% and 48.7% for the first, second, third, and fourth quartiles, respectively). In multivariate analyses, compared with patients in the first PTH quartile, those in the third and fourth quartiles had a significant 35% and 89% increased odds of having metabolic syndrome, respectively.
When taken as a continuous predictor, each standard deviation increase of natural log transformed PTH was associated with a 26% higher odds of having metabolic syndrome. The association of PTH with metabolic syndrome was not modified by age or gender.